Manchester Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Manchester Capital Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Hold	3,000	–	–	0.04%	223
2026 Q1	$260K	Hold	3,000	–	–	0.04%	238
2025 Q4	$254K	Hold	3,000	–	–	0.03%	242
2025 Q3	$218K	Hold	3,000	–	–	0.03%	295
2025 Q2	$197K	Hold	3,000	–	–	0.03%	344
2025 Q1	$212K	Hold	3,000	–	–	0.03%	323
2024 Q4	$197K	Hold	3,000	–	–	0.02%	334
2024 Q3	$212K	Hold	3,000	–	–	0.02%	320
2024 Q2	$199K	Hold	3,000	–	–	0.02%	310
2024 Q1	$204K	Hold	3,000	–	–	0.03%	310
2023 Q4	$185K	Hold	3,000	–	–	0.02%	290
2023 Q3	$177K	Hold	3,000	–	–	0.03%	283
2023 Q2	$179K	Buy	+3,000	New	+$178K	0.02%	282
2021 Q4	–	Sell	-30	Closed	-$2K	–	1055
2021 Q3	$2K	Hold	30	–	–	﹤0.01%	863
2021 Q2	$2K	Hold	30	–	–	﹤0.01%	691
2021 Q1	$2K	Hold	30	–	–	﹤0.01%	593
2020 Q4	$2K	Hold	30	–	–	﹤0.01%	603
2020 Q3	$2K	Hold	30	–	–	﹤0.01%	478
2020 Q2	$2K	Hold	30	–	–	﹤0.01%	525
2020 Q1	$1K	Hold	30	–	–	﹤0.01%	532
2019 Q4	$2K	Buy	+30	New	+$1.48K	﹤0.01%	505

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Manchester Capital Management's IHE Position: Q2 2026 in Review

Manchester Capital Management held its iShares US Pharmaceuticals ETF (IHE) position steady in Q2 2026 at 3,000 shares worth $297K. The position accounts for 0.04% of the portfolio, ranked #223.

Manchester Capital Management first reported a position in IHE in Q4 2019 and has held it in 21 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Manchester Capital Management held 3,000 shares of iShares US Pharmaceuticals ETF worth $297K as of Q2 2026.
Manchester Capital Management left its iShares US Pharmaceuticals ETF share count unchanged in Q2 2026.
iShares US Pharmaceuticals ETF made up 0.04% of Manchester Capital Management's portfolio in Q2 2026, its #223 holding.
Manchester Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2019 and has held it in 21 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.